Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
- 1
- 2
Chronic Myeloid Leukemia (Prescribing Decisions and Payer Landscape in a Crowded and Changing U.S. Market) | Physician & Payer Forum | US | 2014
Despite the comparatively low incidence of chronic myeloid leukemia (CML) in the United States, patient management requires extended durations of therapy, which in turn translates into a…
Patient Access to High-Cost Therapies for CML in LATAM: How Do Payers and Physicians Shape This Crowded and Changing Market? | Physician & Payer Forum | Brazil and Mexico | 2014
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
Patient Access to High-Cost Therapies for CML in China: How Are Payers and Physicians Shaping This Crowded and Changing Market? | Physician & Payer Forum | China | 2014
Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…
Chronic Myelogenous Leukemia: Prescribing Decisions and Payer Landscape in a Crowded and Dynamic Market | Physician & Payer Forum | EU5 | 2014
Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myelogenous leukemia (CML) over the last decade. However, as 2013-approved second-generation TKIs Bosulif (Pfizer’s…
- 1
- 2